Cited by 841Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentMRI in cancer diagnosis

Early Detection of Pancreatic Cancer: Opportunities and Challenges

Open access
Singhi, Aatur D., Koay, Eugene J., Chari, Suresh T., Maitra, Anirban·2019·Gastroenterology

Abstract

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic, surgically unresectable disease. Although the goal of early detection of PDAC is laudable and likely to result in significant improvement in overall survival, the relatively low prevalence of PDAC renders general population screening infeasible. The challenges of early detection include identification of at-risk individuals in the general population who would benefit from longitudinal surveillance programs and appropriate biomarker and imaging-based modalities used for PDAC surveillance in such cohorts. In recent years, various subgroups at higher-than-average risk for PDAC have been identified, including those with familial risk due to germline mutations, a history of pancreatitis, patients with mucinous pancreatic cysts, and elderly patients with new-onset diabetes. The last 2 categories are discussed at length in terms of the opportunities and challenges they present for PDAC early detection. We also discuss current and emerging imaging modalities that are critical to identifying early, potentially curable PDAC in high-risk cohorts on surveillance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.01.259

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Current pancreatic cancer biomarkers lack sufficient sensitivity and specificity for clinical application.

    “However, the current PC biomarkers lack sufficient sensitivity and specificity for clinical application 44,161,170.”

    From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [170]

    The Overview (page unavailable) says that biomarkers meeting the performance requirements for use in asymptomatic screening are not yet available. The Road Ahead (page unavailable) says circulating tumor cell and tumor DNA assays cannot be used for screening or early diagnosis because of limited sensitivity, despite high specificity. The claim extends these screening-specific limitations to all clinical applications and implies both measures are insufficient for current biomarkers generally. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Approximately 85-90% of PDAC cases are ascribed to arise from PanIN lesions, with the remaining 10-15% from cystic precursors.

    “Approximately 85–90% of PDAC cases are ascribed to originate on the backdrop of PanIN lesions, the remaining 10–15% in cystic precursors20.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 9

  1. [9]Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223: 273– 9. 8604907 PMC1235115
  2. [31]Hwang DW, Jang JY, Lee SE, Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg 2012; 397: 93– 102. 20640860
  3. [32]Salvia R, Fernandez-del Castillo C, Bassi C, Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239: 678– 85; discussion 685–7. 15082972 PMC1356276
  4. [45]Parvanescu A, Cros J, Ronot M, Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms:: GNAS-activating mutations in pancreatic carcinogenesis. JAMA Surg 2014; 149: 858– 62. 24898823
  5. [48]Suzuki Y, Atomi Y, Sugiyama M, Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 2004; 28: 241– 6. 15084964
  6. [49]Schmidt CM, White PB, Waters JA, Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007; 246: 644– 51; discussion 651–4. 17893501
  7. [104]Kimura W, Miyata H, Gotoh M, A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 2014; 259: 773– 80. 24253151
  8. [163]Palazzo L, Roseau G, Gayet B, Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy 1993; 25: 143– 50. 8491130
  9. [186]Sharma A, Kandlakunta H, Nagpal SJS, Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology 2018; 155: 730– 739 e3. 29775599 PMC6120785

Cited by

Sorted by citations

Authors
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A.
Affiliations
  • University of Pittsburgh Medical Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Mayo Clinic (US)
Corresponding author
Chari, Suresh T.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-05
Volume
156
Issue
7
Pages
2024-2040
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2913413342
Cited by
841
References
185
Citations by year
2026: 92 · 2025: 150 · 2024: 135 · 2023: 134 · 2022: 120 · 2021: 111 · 2020: 78 · 2019: 20
FWCI
8.09
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (U01 CA196403, R01 CA218004, U01 CA200468)
  • National Institutes of Health (DK108288)
  • GE Healthcare
  • Pancreatic Cancer Action Network
  • Mayo Foundation for Medical Education and Research
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
pancreatic ductal adenocarcinoma, early detection, cancer surveillance, vulnerable populations, familial pancreatic cancer, germline mutations, pancreatitis, mucinous pancreatic cysts, new-onset diabetes, pancreatic imaging, biomarkers
MeSH terms
Animals, Diagnostic Imaging, Humans, Pancreatic Neoplasms, Precancerous Conditions, Predictive Value of Tests, Risk Factors, Biomarkers, Tumor, Incidence, Risk Assessment, Carcinoma, Pancreatic Ductal, Early Detection of Cancer, Molecular Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review